Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年3月2日 - 7:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2024
JIN MEDICAL INTERNATIONAL LTD.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Change of Auditor
On February 26, 2024, DNTW Toronto LLP (“DNTW”)
tendered its resignation as the Company’s independent registered public accounting firm to audit its financial statements for the
year ended September 30, 2023, effective immediately and on the same date.
From September 23, 2023 to February 28, 2024, there
have been no disagreements with DNTW on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure.
During the period from September 23, 2023 to February
28, 2024, there were no “reportable events” (defined below) requiring disclosure pursuant to Item 16F(a)(1)(iv) of Form 20-F.
As used herein, the term “reportable event” means any of the items listed in paragraphs (a)(1)(v)(A)-(D) of Item 16F of Form
20-F.
On March 1, 2024, the Audit Committee approved to
engaged Audit Alliance LLP as the Company’s new independent registered public accounting firm.
During the two fiscal years ended December 31, 2023
and 2022 and up to the date of Audit Alliance LLP’s appointment, neither our Company nor anyone acting on our behalf consulted DNTW
with respect to any of the matters or reportable events set forth in Item 16F(a)(2)(i) and (ii) of Form 20-F.
SIGNATURES
Pursuant to the requirements of
the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
JIN MEDICAL INTERNATIONAL LTD. |
|
|
|
Date: March 1, 2024 |
By: |
/s/ Erqi Wang |
|
|
Erqi Wang |
|
|
Chief Executive Officer |
Jin Medical (NASDAQ:ZJYL)
過去 株価チャート
から 10 2024 まで 11 2024
Jin Medical (NASDAQ:ZJYL)
過去 株価チャート
から 11 2023 まで 11 2024